Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightFurther studies are warranted to determine the efficacy of resistin in clinical use.
📌 3 Maddede Bu Makale
Özet
Objective: Resistin, a cysteine-rich peptide, is associated with atherosclerosis and diabetes. Resistin levels increase corresponding to coronaryartery disease (CAD) and heart failure severity. Since resistin level tends to elevate with symptomatic heart failure, it is expected to be associatedwith left ventricular end-diastolic pressure (LVEDP). However, there is no relevant literature on the relationship between resistin levels andLVEDP. We aimed to evaluate the association between resistin levels and LVEDP, severity of CAD, carotid intima-media thickness (CIMT), andechocardiographic diastolic dysfunction parameters.Methods: For this study, 128 euvolemic patients with creatinine clearance >50 mg/dL and without acute coronary syndrome, who had typicalchest pain or were stress test positive, were enrolled. Resistin level was measured by Enzyme-linked immunosorbent assays (ELISA) method.Severe CAD is defined as ≥50% stenosis in one of the major coronary arteries. LVEDP was measured during left heart catheterization.Results: After coronary angiography, 60 patients (46.9%) had severe CAD. The mean LVEDPs were similar for patients with and without severeCAD (p=0.480). The resistin levels did not differ between the groups (p=0.154). The resistin levels did not correlate with LVEDP (r=−0.045, p=0.627),ejection fraction (EF; r=0.110, p=0.228), the Gensini score (r=−0.091, p=0.328), and CIMT (r=0.082, p=0.457). No significant correlation was foundbetween the echocardiographic diastolic dysfunction parameters and resistin levels.Conclusion: There was no significant correlation between resistin level and LVEDP, CAD severity, echocardiographic diastolic dysfunction parameters,and CIMT. Further studies are warranted to determine the efficacy of resistin in clinical use.